Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.
Zsuzsanna Bago-HorvathMargaretha RudasChristian F SingerRichard GreilMarija BalićSigurd F LaxWerner KwasnyWolfgang HullaMichael GnantMartin FilipitsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Determination of molecular subtypes by IHC is an independent prognostic factor for recurrence and death in premenopausal women with early-stage, hormone receptor-positive breast cancer but is not predictive for outcome of adjuvant treatment with tamoxifen/goserelin or CMF.See related commentary by Hunter et al., p. 5543.
Keyphrases
- early breast cancer
- positive breast cancer
- early stage
- prognostic factors
- postmenopausal women
- clinical trial
- study protocol
- phase iii
- sentinel lymph node
- single molecule
- squamous cell carcinoma
- phase ii
- randomized controlled trial
- molecularly imprinted
- breast cancer risk
- high resolution
- smoking cessation
- replacement therapy
- mass spectrometry
- rectal cancer